HOUSTON, May 1, 2019 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
that its manufacturing partner has delivered the first
single-use cartridges capable of delivering the therapy targeting
cellulite reduction.
The cartridge attaches to the treatment head and is designed to
be used for a single patient cellulite treatment and then
replaced. The cartridge is capable of delivering
higher-powered acoustic pulses at greater depths than the Company's
tattoo removal cartridge, and both cartridges can be used with the
same higher-powered pulse generating console, creating a true
platform technology with a range of potential uses in the
practitioner's office. Neither the cartridge nor the device
has been cleared by the FDA.
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
"We are very enthusiastic about the flexibility that our
interchangeable treatment heads will bring to the practitioners
that partner with us for the treatment of cellulite reduction and
tattoo removal," commented Dr. Chris
Capelli, President, CEO and co-founder of Soliton. "Our
therapy will be delivered through single-use cartridges that are
designed to be used for one patient treatment. Once our device is
cleared by the FDA, we expect to deliver a recurring revenue stream
and drive top-line growth for the Company."
Dr. Capelli added: "We believe that this recurring revenue model
will be readily adopted by the marketplace as other aesthetic
technologies have led the way with pay-per-use models. We believe
practitioners will be enthusiastic about our technology that, upon
FDA clearance, could be used across multiple indications."
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first planned commercial product is designed to use rapid
pulses of designed acoustic shockwaves in conjunction with existing
lasers to accelerate the removal of unwanted tattoos (RAP device).
In addition, higher energy versions of acoustic pulse devices are
in early stages of development for potential stand-alone treatment
of cellulite and other indications. Both products
are investigational and are not available for sale in the United States.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of the Soliton RAP
technology, including the cellulite treatment cartridge, to prove
safe and effective at reducing cellulite, for the Company's devices
to achieve FDA clearance for the tattoo and cellulite indications,
and whether the Company's intended revenue model will be accepted
by the market. These statements relate to future events,
future expectations, plans and prospects. Although Soliton believes
that the expectations reflected in such forward-looking statements
are reasonable as of the date made, expectations may prove to have
been materially different from the results expressed or implied by
such forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2018
we filed with the SEC and updated from time to time in our Form
10-Q filings and in our other public filings with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-announces-completion-of-new-replaceable-cartridge-to-target-cellulite-reduction-300841526.html
SOURCE Soliton, Inc.